Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CRH
CRH
|
+$2.05B |
| 2 |
Texas Instruments
TXN
|
+$1.69B |
| 3 |
NVIDIA
NVDA
|
+$1.36B |
| 4 |
Starbucks
SBUX
|
+$1.2B |
| 5 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$949M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$2.77B |
| 2 |
Microsoft
MSFT
|
+$1.3B |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$1.22B |
| 4 |
iShares US Real Estate ETF
IYR
|
+$1.11B |
| 5 |
Procter & Gamble
PG
|
+$915M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.33% |
| 2 | Consumer Discretionary | 7.25% |
| 3 | Financials | 7.18% |
| 4 | Communication Services | 6.16% |
| 5 | Healthcare | 5.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3001
Ocugen
OCGN
$431M
| $441K | ﹤0.01% |
+284,433
| New | +$443K |
|
3002
abrdn Physical Gold Shares ETF
SGOL
$7.41B
| $441K | ﹤0.01% |
19,830
| – | – |
|
3003
Forrester Research
FORR
$229M
| $440K | ﹤0.01% |
25,771
-1,050
| -4% | -$19.3K |
|
3004
CALL
ODDITY Tech
ODD
$652M
| $440K | ﹤0.01% |
+11,200
| New | +$417K |
|
3005
Stoke Therapeutics
STOK
$2.11B
| $439K | ﹤0.01% |
32,501
+11,877
| +58% | +$160K |
|
3006
DXC Technology
DXC
$1.73B
| $439K | ﹤0.01% |
22,974
-58,693
| -72% | -$1.1M |
|
3007
Relmada Therapeutics
RLMD
$520M
| $438K | ﹤0.01% |
145,999
| – | – |
|
3008
N-able
NABL
$938M
| $437K | ﹤0.01% |
28,721
-110,261
| -79% | -$1.45M |
|
3009
National Beverage
FIZZ
$3.01B
| $437K | ﹤0.01% |
8,535
-13,225
| -61% | -$619K |
|
3010
Core Laboratories
CLB
$520M
| $437K | ﹤0.01% |
21,528
-29,221
| -58% | -$517K |
|
3011
Aurinia Pharmaceuticals
AUPH
$2.04B
| $435K | ﹤0.01% |
76,259
-96,465
| -56% | -$508K |
|
|
FFIC
3012
DELISTED
Flushing Financial
FFIC
| $435K | ﹤0.01% |
33,060
-19,136
| -37% | -$233K |
|
|
YSG
3013
Yatsen Holding
YSG
$320M
| $433K | ﹤0.01% |
162,969
+157,969
| +3,159% | +$564K |
|
3014
Kyverna Therapeutics
KYTX
$484M
| $433K | ﹤0.01% |
57,749
+14,655
| +34% | +$224K |
|
3015
Mayville Engineering Co
MEC
$616M
| $433K | ﹤0.01% |
25,997
-740
| -3% | -$11.2K |
|
|
INFN
3016
DELISTED
Infinera Corporation Common Stock
INFN
| $432K | ﹤0.01% |
70,926
-109,778
| -61% | -$581K |
|
3017
Sprott Physical Gold and Silver Trust
CEF
$8.06B
| $431K | ﹤0.01% |
19,561
| – | – |
|
|
GNTY
3018
DELISTED
Guaranty Bancshares
GNTY
| $431K | ﹤0.01% |
13,667
-2,989
| -18% | -$87.6K |
|
3019
Cellectar Biosciences
CLRB
$20.2M
| $430K | ﹤0.01% |
5,740
-5,533
| -49% | -$531K |
|
3020
Grindr
GRND
$2.94B
| $430K | ﹤0.01% |
35,103
-525
| -1% | -$5.24K |
|
3021
SI-BONE Inc
SIBN
$835M
| $430K | ﹤0.01% |
33,221
-21,332
| -39% | -$305K |
|
|
HSHP
3022
Himalaya Shipping
HSHP
$749M
| $429K | ﹤0.01% |
46,855
-21,406
| -31% | -$182K |
|
|
TEAD
3023
Teads Holding Co
TEAD
$66.9M
| $428K | ﹤0.01% |
85,928
-11,917
| -12% | -$52.9K |
|
3024
CALL
BRC Group Holdings
RILY
$289M
| $427K | ﹤0.01% |
+24,200
| New | +$622K |
|
3025
i3 Verticals
IIIV
$341M
| $427K | ﹤0.01% |
19,327
-12,505
| -39% | -$264K |
|
Similar funds
Barclays's Q2 2024 Portfolio in Review
As of Q2 2024, Barclays held 5,455 positions worth $327B, up 14% from $288B the previous quarter. Its ten largest holdings account for 42% of the portfolio.
Barclays deployed $29.4B of net new capital in Q2 2024, opening 406 new positions and adding to 1,053 existing holdings. Its largest new stake was Ferrovial N.V. Ordinary Shares: 4,837,593 shares worth $186M.
By sector, the portfolio is most concentrated in Technology at 22% of assets, down from 24% a quarter earlier, followed by Consumer Discretionary and Financials.
On the sell side, the largest reduction was Apple, an estimated $2.77B trimmed.
- Barclays's largest Q2 2024 buy was Ferrovial N.V. Ordinary Shares: 4,837,593 shares worth $186M.
- Barclays added most to CRH in Q2 2024, an estimated $2.05B increase.
- Barclays's biggest Q2 2024 reduction was Apple, cutting an estimated $2.77B.
- Barclays fully exited Pioneer Natural Resource Co. in Q2 2024, selling an estimated $212M.
- Barclays's ten largest holdings make up 42% of its $327B portfolio in Q2 2024.
- Barclays opened 406 new positions and closed 646 in Q2 2024.
- Barclays's portfolio value rose 14% quarter-over-quarter to $327B.
Based on Barclays's 13F filing for Q2 2024, filed 14 Aug 2024.